StockNews.com Upgrades Mesoblast (NASDAQ:MESO) to “Hold”

Mesoblast (NASDAQ:MESO) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research note on Friday, January 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Mesoblast has a consensus rating of “Hold” and a consensus price target of $13.67.

Mesoblast Price Performance

Shares of NASDAQ MESO traded down $0.50 during midday trading on Tuesday, hitting $6.60. The stock had a trading volume of 231,085 shares, compared to its average volume of 1,747,459. The company’s 50-day simple moving average is $3.99 and its 200 day simple moving average is $2.81. The firm has a market cap of $753.59 million, a P/E ratio of -5.89 and a beta of 3.59. Mesoblast has a fifty-two week low of $1.61 and a fifty-two week high of $10.24.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Mesoblast stock. Prosperity Wealth Management Inc. purchased a new position in Mesoblast Limited (NASDAQ:MESO) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 64,150 shares of the company’s stock, valued at approximately $79,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.